Navigation Links
EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Date:9/10/2007

n preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
7. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015   EVO Aesthetic ... the leading provider for non-invasive aesthetics in ... tattoo removal treatments with the Astanza Duality laser. The ... well being through various medical and laser procedures. Their ... unwanted ink a clear solution to their tattoo regret. ...
(Date:7/2/2015)... Pharma Major Lupin Limited today announced ... Russia subject to certain closing conditions. ... which recorded RUB 765 billion in sales, placing it as ... in 2014 (IMS Health). For over a decade, Russian pharmaceutical ... this trend, projecting Russia to be ...
(Date:7/2/2015)... , July 2, 2015 ... (Homofermentative & Heterofermentative), Species (Lactobacillus, Pediococcus & Enterococcus), Enzymes ... and Forecast to 2020", Silage Inoculants & Enzymes Market ... a CAGR of 4.0% from 2015 to 2020. ... igures spread through 194 P ...
Breaking Medicine Technology:EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4
... for November 11, 2008 at 9:00 am ET, ... Anesiva,Inc. (Nasdaq: ANSV ) today announced that ... formulation of capsaicin, narrowly missed its,primary endpoint of ... at four to 32 hours post-surgery. The same,measure ...
... NOVATO, Calif., Nov. 10 Raptor,Pharmaceuticals Corp. ... today announced that the Company has entered ... d,Angers ("CHU d,Angers") of France to,evaluate Raptor,s ... Phase II clinical trial in patients with ...
Cached Medicine Technology:Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring 2Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring 3Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring 4Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring 5Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 2Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 3Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 4Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 5Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 6
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... Yisrayl Hawkins, ... new article this week that he says will reveal biblical truth and expose popular ... “Why Does Your Bible Say Don’t Have Sex”, immediately goes into the core of ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of ... in the Lone Star State. The premium frozen yogurt chain was listed as #22 on ... June 19 in the Village at Bachman Lake, is located at:, 3701 W. Northwest Highway, ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... structure retrofit project at the University of Minnesota, they knew it would save ... would also be an award-winning choice: the total energy savings after installation was ...
(Date:7/2/2015)... ... July 02, 2015 , ... “ LIFX ” was featured on NewsWatch as ... available to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted ... smart light bulbs on the market. , According to the U.S. Department of Energy, ...
(Date:7/2/2015)... Silver Spring, Md. (PRWEB) , ... July 02, 2015 , ... ... mile mark in his solo cross-country walk to raise awareness and money for the ... ago and expects to arrive at PHA’s headquarters near Washington, D.C. by mid-September. He ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3
... 23 Two carotid stenting,trials examining outcomes ... results that are comparable to guidelines established ... treated with carotid artery,surgery. The results of ... clinical trials session at the Cardiovascular Research,Foundation,s ...
... Product Acquisition, SHOREVIEW, Minn., Oct. 23 ... caused by Community Acquired - MRSA (CA-MRSA),Superbugs, Key ... Group of,Companies, announced that they have mobilized and ... of information and acquisition of cleaning,products to combat ...
... AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ... where new drugs can be developed and tested ... ever before. , Among the studies presented ... novel insulin-like growth factor receptor enzyme inhibitors, both ...
... the Cure to Join Nationwide Campaign Challenging ... in Breast Cancer Care, Survival, DETROIT, Oct. 23 ... will host events to launch Metro Detroit,s participation,in the Komen ... of the 25-city campaign to elevate breast cancer on,the national ...
... Largest Increase Since 1998, DALLAS, Oct. 23 ... the year before, marking a 4.4,percent increase in total ... Enrollment Report published by the National,Association of Dental Plans ... is the top reason cited by consumers for not ...
... to severe chronic liver disease can be predicted with ... recent study conducted by researchers at New York University ... to the increased incidence of chronic hepatitis in the ... need for non-invasive methods to replace or supplement liver ...
Cached Medicine News:Health News:Real-World Studies of Carotid Artery Stenting Demonstrate Results Comparable to Guidelines for Patients Treated With Surgery 2Health News:Real-World Studies of Carotid Artery Stenting Demonstrate Results Comparable to Guidelines for Patients Treated With Surgery 3Health News:Real-World Studies of Carotid Artery Stenting Demonstrate Results Comparable to Guidelines for Patients Treated With Surgery 4Health News:Key Cleaning Solutions Products Utilized to Combat Community Acquired - MRSA (CA-MRSA) Are Succeeding In Killing Superbugs Where Normal Cleaning Practices and Products Are Not 2Health News:Key Cleaning Solutions Products Utilized to Combat Community Acquired - MRSA (CA-MRSA) Are Succeeding In Killing Superbugs Where Normal Cleaning Practices and Products Are Not 3Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 2Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 3Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 4Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 5Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 6Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 7Health News:Susan G. Komen for the Cure, Karmanos Cancer Institute, Community Leaders, Breast Cancer Survivors and Activists to Gather at Forum and Call for Action on Breast Cancer 2Health News:Population Covered by Dental Benefits Increases 2Health News:MRI predicts liver fibrosis, study says 2
Non-Cantilevered, "Teardrop" Ringed Forceps. ("fixation clamp") For vasectomy and other procedures. Ring ovoid approximately 6.0 mm in diameter....
... Stethoscope Module is an inconspicuous, lightweight, battery-operated instrument ... hear body functions amplified., ,The module controls ... switch, a tone switch, a stethoscope hearing aid ... switch will allow the user to select between ...
... Standard snap ring receiver ... nursing., ,Impressions of your ... ,Westone custom products for the ... worldwide network of hearing healthcare ...
... The many benefits of fibre bronchoscopy: ... standard by which all other fibre bronchoscopes ... fibre bronchoscopes from PENTAX, including the FB-19TV, ... very slim FB-10V and the pediatric FB-8V, ...
Medicine Products: